sur Zomedica Corp. (NASDAQ:ZOM)
Zomedica Reports Record Revenue Growth in Q3 2025
Zomedica Corp, an animal health company, announced a significant 16% revenue increase for Q3 2025, reaching $8.1 million. This marks their highest quarterly earnings to date and the 19th consecutive quarter of year-over-year revenue growth. CEO Larry Heaton attributes this success to the strong demand for their PulseVet® and Assisi® therapeutic devices, alongside continued growth in their diagnostic product line, including the TRUFORMA® platform.
The introduction of Zomedica's new Development Services segment contributed $0.7 million, illustrating diversification in revenue streams. Growth in the Diagnostic segment reached 51%, supplemented by robust international sales, driven by strategic partnerships. Operating expenses decreased by $0.5 million, while gross margins remained at 67%.
Zomedica ended Q3 with $54 million in liquidity, positioning them well for future expansion and profitability.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Zomedica Corp.